Protocol Ledger

NCT04400474 · Phase II · COMPLETED

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Interventional Phase II clinical trial protocol NCT04400474 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-07 Enrollment: 93 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04400474
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04400474
Protocol FieldVerified Registry Value
NCT IdentifierNCT04400474
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment93 participants (ACTUAL)
Registered Start Date2020-10-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI